News
PBYI
5.02
+0.50%
0.03
Weekly Report: what happened at PBYI last week (0408-0412)?
Weekly Report · 4d ago
Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts
NASDAQ · 04/11 22:00
Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Puma Biotechnology's estimated fair value is US$10.76 based on 2 Stage Free Cash Flow to Equity Current share price of US$5.83 suggests Puma Biotech is potentially 46% undervalued. The company appears to be trading at a 46% discount to its actual value. We use the Discounted Cash Flow model to estimate the value of PumaBiotechnology, Inc. (NASDAQ:PBYI)
Simply Wall St · 04/10 10:29
Weekly Report: what happened at PBYI last week (0401-0405)?
Weekly Report · 04/08 09:01
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. Granted an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive employee. Puma is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
Barchart · 04/03 16:30
Weekly Report: what happened at PBYI last week (0325-0329)?
Weekly Report · 04/01 09:01
Weekly Report: what happened at PBYI last week (0318-0322)?
Weekly Report · 03/25 09:01
Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?
NASDAQ · 03/22 13:25
Puma Biotech cleared to trial Takeda-partnered breast cancer therapy in U.S.
Puma Biotech cleared to trial Takeda-partnered breast cancer therapy in U.S. FDA greenlighted a Phase 2 trial to investigate oral kinase inhibitor alisertib in patients with breast cancer. Puma Biotechnology plans to start ALISCA-Breast1 in H2 2024.
Seeking Alpha · 03/20 14:06
Puma Biotechnology: FDA Allows To Proceed With Clinical Development Of Alisertib
NASDAQ · 03/20 12:48
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
Puma Biotechnology's alisertib was approved in the U.S. For the treatment of patients with early stage breast cancer. The company says the FDA has approved the drug. Puma plans to start a clinical trial in the second half of 2024. The drug is being developed to treat patients with HER2-negative metastatic breast cancer, the company says.
Barchart · 03/20 07:30
COIN, HUT and WNW among pre-market losers
On the Move COIN, HUT and WNW among pre-market losers. ShiftPixy -29% announces pricing of $5 million offering priced at-the-market. Peraso -17% after Q4 earnings release. Bitcoin tumbles from all-time high.
Seeking Alpha · 03/19 12:44
Is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 40% ROE Better Than Average?
Puma Biotechnology, Inc. (NASDAQ:PBYI) has a 40% return on equity. Return on Equity is the rate of return a company earns for its shareholders. The average for the Biotech industry is 17%. Puma Biotech has a good ROE of 40%. The company uses a high amount of debt to increase its returns.
Simply Wall St · 03/19 10:51
Puma Biotechnology dips after dismissal of its suit was granted by a federal judge
Puma Biotechnology dips after dismissal of its suit was granted by a federal judge. A federal judge granted AstraZeneca's motion to dismiss Puma Biotech from a lawsuit seeking royalties from its Tagrisso medicine. The drug is used to treat adults with lung cancer.
Seeking Alpha · 03/18 19:36
Weekly Report: what happened at PBYI last week (0311-0315)?
Weekly Report · 03/18 09:01
Weekly Report: what happened at PBYI last week (0304-0308)?
Weekly Report · 03/11 09:01
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
NASDAQ · 03/05 18:00
Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise
NASDAQ · 03/04 16:24
Weekly Report: what happened at PBYI last week (0226-0301)?
Weekly Report · 03/04 09:01
Puma Biotechnology Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/01 20:03
More
Webull provides a variety of real-time PBYI stock news. You can receive the latest news about Puma Biotechnology Inc through multiple platforms. This information may help you make smarter investment decisions.
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.